Braeburn Pharmaceuticals Applauds Repeal of HB2

PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. made the following statement today in response to the repeal of House Bill 2 (HB2).

"Diversity and a commitment to inclusion is core to the identity of Braeburn Pharmaceuticals. Last year, we decided to proceed with plans to develop a research facility in Durham County despite our deep concerns and opposition to HB2, vowing to do our part to help overturn it," said President and CEO Behshad Sheldon, Braeburn Pharmaceuticals. "We applaud Governor Cooper and legislative leaders for passing a compromise solution that removes HB2 and takes an important step to protect the rights of all citizens in North Carolina. We will continue to advocate for progressive public policy and support those who share our commitment to diversity and nondiscrimination."

About Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn's commercial product, Probuphine^® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.

Contacts:

Sherry Feldberg for Braeburn Pharmaceuticals
MSLGROUP
781-684-0770
braeburnpharma@mslgroup.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/braeburn-pharmaceuticals-applauds-repeal-of-hb2-300432936.html

SOURCE Braeburn Pharmaceuticals, Inc.